1.Pulmonary Arterial Aneurysm with Thrombus Formation and Atrial Septal Defect with Pulmonary Hypertension
Sime Raymond B. Fernandez ; Jessie F. Orcasitas
Philippine Journal of Internal Medicine 2019;57(1):46-50
Introduction:
Pulmonary arterial aneurysm (PAA) is a rare condition with varying symptomatology. Patients are often referred due to incidental finding of intrathoracic mass on chest radiograph. Common causes include structural cardiac and vascular abnormality, pulmonary hypertension, infection, vasculitis, connective tissue disease, and trauma.
Case presentation:
A 37-year-old female came in due to shortness of breath associated with easy fatigability, exertional dyspnea, orthopnea, and occasional palpitations. Workup revealed 2D echocardiography findings of atrial septal defect (ASD) with left to right shunt; dilated right atrium and right ventricle; severe pulmonary hypertension; dilated main pulmonary artery. Contrast-enhanced computed tomography (CT) angiography showed PAA in the right main trunk, left and right pulmonary artery with thrombus formation. Cardiac catheterization and hemodynamic study were intended prior to definitive surgical treatment however patient did not opt to proceed. She was managed with warfarin, bisoprolol, digoxin, and trimetazidine. In spite of symptom relief, the patient still needs regular follow-up for reassessment to monitor disease progression.
Discussion:
Pulmonary arterial aneurysm (PAA) is a rare complication of ASD, a common congenital heart disease. In this case, it presented as a mediastinal mass with nonspecific symptoms diagnosed after routine chest x-ray, verified through echocardiogram. Contrast-enhanced CT angiography ruled out aortic aneurysm and provided additional information of the extent of thrombus formation. However, pulmonary angiography still remains the diagnostic gold standard. Due to the rarity of the disease, optimal treatment of PAA is still uncertain. It is reasonable, however, to treat conservatively for asymptomatic patient with no significant pulmonary hypertension. A more aggressive surgical approach has been advocated for patients with complications.
Conclusion
It is important to emphasize that PAA can present with non-specific manifestations thus high index of suspicion is critical for the diagnosis. It is also vital for early detection of the aneurysm and correction of the etiology to prevent disease morbidity and mortality.
Thrombosis
;
Heart Septal Defects, Atrial
2.The yield of malignancy for early fixation versus routine fixation of Pleural fluid samples
Ria Katrina B. Cortez ; Richard Baron B. Yee ; Jessie F. Orcasitas
Philippine Journal of Internal Medicine 2022;60(3):205-210
Background:
The etiology of pleural effusion remains unclear in nearly 20% of cases. One way to diagnose malignancy is
by doing pleural fluid cytology. There are factors that influence the yield of pleural fluid cytology and one of them is appropriate and timely fixation of samples. Currently, there is no local consensus regarding the timing with which the specimen should be fixed.
Objective:
The study aims to compare the yield of malignancy between early fixation versus usual fixation of pleural fluid
samples, meaning there is no set time for fixation to be done.
Methodology:
The study employed a prospective cross-sectional research design. All patients with pleural effusion who
fulfilled the criteria set by the study were included. Two sets of pleural fluid samples were collected amounting to 20cc each. First sample was assigned as Bottle #1 and placed immediately with fixative while the second sample was assigned as Bottle #2. Bottle #2 underwent routine fixation which follows no fixed or standard time of fixation. The time difference between the fixation of two sample groups greatly varied with Bottle #1 fixed immediately right after collection while Bottle#2 depends on the time it will be processed by the laboratory personnel. Both samples were submitted for cell block and cell cytology reading.
Results:
Characteristics of the 55 patients included in the study showed age group range from 41 to 65 years of age, with 27 male and 28 female patients. Only one third had history of smoking. There were 21.82% who had family history of cancer and with and suspicious mass on chest radiograph. Out of 55 patients, 29 patients had history of previous diagnosis of cancer, 23 had recurrent pleural effusion, and 28 had chest radiograph with suspicious nodules. Based on gross appearance, there were 20 serous and 21 sanguineous pleural fluid noted. Mean cell count was high (1,115.50 ± 741.02) with lymphocytic predominance (82.56 ± 24.46). Elevated protein concentration (5,388.25 ± 8,230.46) and LDH (484.17 ± 248.72) were noted. Glucose (8.78 ± 6.68 mmol/L) was low. There were 21 patients who had high WBC, 24 with high protein and 16 with elevated LDH. There were 3 patients who were positive for AFB and none for KOH. Comparative analysis showed that the pleural fluid samples assigned to the routinely fixed group which were handed to the nurse after thoracentesis, then forwarded to the laboratory through a ward laboratory aide or patient watcherfor fixation with with 95% alcoholby thelaboratory personnel significantly had a longer duration of 406.62 minutes as compared to immediately fixed at 12.27 minutes (P<0.01). For diagnosis of malignancy, significantly more cases were diagnosed in the immediately fixed group with 36.36% cases versus 18.18% (p=0.016).
Conclusion
Among patients with suspected malignant pleural effusions, early fixation of pleural fluid samples resulted in
higher histopathology yields as compared to those fixed after going through the routine fixation.
Pleural Effusion, Malignant
3.Rifampicin-Induced Thrombocytopenia: A case report
Denise C. De Los Reyes ; Maria Carmen D. Ang ; Heide P. Abdurahman ; Jessie F. Orcasitas
Philippine Journal of Internal Medicine 2021;59(1):62-66
INTRODUCTION:
The worldwide prevalence of adverse drug reactions (ADR) to anti-TB medication ranges from 8% to
85%. Major adverse reactions include hepatic, renal, and hematologic disorders of which, Rifampicin-induced thrombocytopenia is one of these rare complications.
CASE:
A 58-year-old Filipino male developed respiratory and gastrointestinal bleeding with a severe drop in platelet count after several days of anti-tuberculosis (anti-TB) medications. The patient had oral mucosal petechiae, blood-streaked sputum, and epistaxis. The symptoms progressed to the formation of small adherent clots beneath the tongue, gum bleeding, melena, massive epistaxis, and hemoptysis with continued intake of the anti-TB drugs. The patient had anemia, normal WBC and differential count, and thrombocytopenia of 3 x 10^3/uL, a drop from 235 x 10^3/uL five days prior. The bleeding resolved with the discontinuation of the drugs. A slow graded oral challenge to each of the drugs was done to identify the culprit medication. There was a recurrence of bleeding and a decrease in the platelet count after administration of rifampicin. The anti-TB medications were modified not to include rifampicin. The patient was discharged with no signs of bleeding and a normal complete blood count.
CONCLUSION
TB is a prevalent disease in our country, and its medications can cause adverse drug reactions. Rifampicin-induced thrombocytopenia is a rare and life-threatening condition that physicians must be aware of and able to recognize promptly and treat properly to prevent recurrence of similar cases in the future. The patient should be forewarned not to take rifampicin and any fixed-dose combination drugs containing rifampicin.
Rifampin
;
Thrombocytopenia
;
Blood Platelets
;
Tuberculosis
4.Identifying COVID-19 confirmed patients at elevated risk for mortality and need of mechanical ventilation using a novel criteria for Hyperinflammatory Syndrome: A retrospective cohort, single-center, validation study
Jayvee Rho-An D. Descalsota ; Abdul Walli R. Cana ; Inofel I. Chin ; Jessie F. Orcasitas
Acta Medica Philippina 2024;58(Early Access 2024):1-12
Background and Objectives:
A mounting evidence links dysregulated immune response to cases of fatal pneumonia seen in COVID-19 infection. We aimed to validate the COVID-19-associated Hyperinflammatory Syndrome (cHIS) score, a novel clinical tool devised to identify those at risk for adverse outcomes, in a local population and investigate the relationship of cHIS score taken at admission and the risk of mortality and the need of mechanical ventilation
Methods:
This retrospective cohort study analyzed the sociodemographic, clinical, and laboratory data of 1,881 COVID-19 patients admitted at a tertiary hospital in Davao City, Philippines from January to December 2021. We calculated the cHIS score, composed of six clinical and laboratory criteria from admission, and used multivariate logistic regression to determine the risk of mortality and need of mechanical ventilation.
Results:
The cHIS score taken at admission, regardless of cut-off value, was a significant predictor of mortality (OR 0.979 [99% CI 0.894-1.064]) and need of mechanical ventilation (OR 0.586 [99% CI 0.4975-0.6745]). Using the Youden Index, a cut-off cHIS score of 3 or more was a better predictor of mortality (sensitivity, 88.59%; specificity, 71.72%), and a cut-off score of 2 or more was a better predictor of need of mechanical ventilation (sensitivity, 84.02%; specificity, 70.82%) than other cut-off cHIS scores.
Conclusion
Among COVID-19 patients, the cHIS score at admission correlated with the risk of mortality and the need of mechanical ventilation. Cutoff scores of 3 and 2 had the optimal sensitivities and specificities to predict the risk of mortality and the need of mechanical ventilation, respectively.
COVID-19
;
Inflammation
;
Mortality
;
Respiration, Artificial
;
Cytokine Release Syndrome
5.Short-acting β2-agonist prescription patterns in patients with asthma in the Philippines: Results from SABINA III
Dina V. Diaz ; Leilanie A. Nicodemus ; Evangeline L. Parena-Santiago ; Marie Elaine V. Capalla ; Ronnie Z. Samoro ; Bryna Kimberly Bayate-Jabines ; Jessie F. Orcasitas ; Miranila Hernandez-Matibag ; Ronnel S. Matibag ; Janet C. Bernardo ; Erica Frances H. Garcia ; Maarten JHI Beekman
Acta Medica Philippina 2020;54(Online):1-13
Objectives:
As asthma is a chronic inflammatory disease of the airways, anti‑inflammatory treatment should be
positioned at the forefront of guideline-directed asthma care. However, patients tend to rely on short-acting β2-
agonists (SABAs) for rapid-onset symptom relief. The impact of SABA overuse and associated clinical outcomes
have been investigated extensively in Europe and North America. Limited data are available from countries in Asia, Africa, Latin America, and the Middle East. The SABA use IN Asthma (SABINA) III program, a large multicountry, observational study, was undertaken to describe the global extent of SABA use and its potential contribution to suboptimal disease control. As part of the SABINA III study, we aimed to characterize SABA prescription collection and asthma-related clinical outcomes among patients in the Philippines.
Methods:
This nationwide, observational, cross-sectional, SABINA III study included patients (aged ≥12 years) with a documented asthma diagnosis recruited between May 2019 and January 2020 from 10 sites in the Philippines. Demographics, disease characteristics and prescribed asthma treatments, including SABA and inhaled corticosteroids (ICS) in the 12 months preceding study start, were recorded during a single visit, and transcribed onto an electronic case report form (eCRF). Patients were classified by investigator‑defined asthma severity, guided by the 2017 Global Initiative for Asthma (GINA) report and practice type, either primary or pulmonary medicine specialist care.
Results:
Of 245 patients analyzed, 63.3% were classified as having moderate-to-severe asthma (GINA steps 3−5), and most patients (63.3%) were enrolled by pulmonary medicine specialists. Overall, 33.1% (n=81) of patients had experienced ≥1 severe exacerbation in the previous 12 months and 18.4% (n=45) of patients had uncontrolled asthma. With respect to asthma treatments, a total of 6.5% (n=16), 40.4% (n=99), and 2.4% (n=6) of patients were prescribed SABA monotherapy, SABA in addition to maintenance therapy, and ICS, respectively, in the 12 months prior to their study visit. Most patients (n=156 [63.7%]) received prescriptions of fixed‑dose combinations of ICS and long-acting β2-agonists. SABA over-prescription, defined as ≥3 SABA canister prescriptions per year, was observed in 10.6% (n=21) of patients. Additionally, 25.6% (n=23) of
patients classified as having mild asthma were prescribed either nebulized SABA (n=17) or oral SABA (n=6). Nearly one-third of patients (n=75 [30.6%]) had purchased over-the-counter (OTC) SABA, and 46.9% (n=115) were prescribed antibiotics.
Conclusions
In this SABINA III Philippines study cohort, more than 10% of patients were over-prescribed SABA
canisters. Additionally, prescriptions for oral or nebulized SABA, the purchase of non-prescription (OTC) SABA,
and the high percentage of prescriptions for antibiotics warrant country-wide improvements in asthma care and management.
Asthma
;
Bronchodilator Agents
;
Prescriptions
6.Short-acting β2-agonist prescription patterns in patients with asthma in the Philippines: Results from SABINA III
Dina V. Diaz ; Leilanie A. Nicodemus ; Evangeline L. Parena-Santiago ; Marie Elaine V. Capalla ; Ronnie Z. Samoro ; Bryna Kimberly Bayate-Jabines ; Jessie F. Orcasitas ; Miranila Hernandez-Matibag ; Ronnel S. Matibag ; Janet C. Bernardo ; Erica Frances H. Garcia ; Maarten JHI Beekman
Acta Medica Philippina 2023;57(11):12-24
Objectives:
As asthma is a chronic inflammatory disease of the airways, anti-inflammatory treatment should be positioned at the forefront of guideline-directed asthma care. However, patients tend to rely on short-acting β2-agonists (SABAs) for rapid-onset symptom relief. The impact of SABA overuse and associated clinical outcomes have been investigated extensively in Europe and North America. Limited data are available from countries in Asia, Africa, Latin America, and the Middle East. The SABA use IN Asthma (SABINA) III program, a large multicountry, observational study, was undertaken to describe the global extent of SABA use and its potential contribution to suboptimal disease control. As part of the SABINA III study, we aimed to characterize SABA prescription collection and asthma-related clinical outcomes among patients in the Philippines.
Methods:
This nationwide, observational, cross-sectional, SABINA III study included patients (aged ≥12 years) with a documented asthma diagnosis recruited between May 2019 and January 2020 from 10 sites in the Philippines. Demographics, disease characteristics and prescribed asthma treatments, including SABA and inhaled corticosteroids (ICS) in the 12 months preceding study start, were recorded during a single visit, and transcribed onto an electronic case report form (eCRF). Patients were classified by investigator-defined asthma severity, guided by the 2017 Global Initiative for Asthma (GINA) report and practice type, either primary or pulmonary medicine specialist care.
Results:
Of 245 patients analyzed, 63.3% were classified as having moderate-to-severe asthma (GINA steps 3−5), and most patients (63.3%) were enrolled by pulmonary medicine specialists. Overall, 33.1% (n=81) of patients had experienced ≥1 severe exacerbation in the previous 12 months and 18.4% (n=45) of patients had uncontrolled asthma. With respect to asthma treatments, a total of 6.5% (n=16), 40.4% (n=99), and 2.4% (n=6) of patients were prescribed SABA monotherapy, SABA in addition to maintenance therapy, and ICS, respectively, in the 12 months prior to their study visit. Most patients (n=156 [63.7%]) received prescriptions of fixed-dose combina-tions of ICS and long-acting β2-agonists. SABA over-prescription, defined as ≥3 SABA canister prescriptions per year, was observed in 10.6% (n=21) of patients. Additionally, 25.6% (n=23) of patients classified as having mild asthma were prescribed either nebulized SABA (n=17) or oral SABA (n=6). Nearly one-third of patients (n=75 [30.6%]) had purchased over-the-counter (OTC) SABA, and 46.9% (n=115) were prescribed antibiotics.
Conclusions
In this SABINA III Philippines study cohort, more than 10% of patients were over-prescribed SABA canisters. Additionally, prescriptions for oral or nebulized SABA, the purchase of non-prescription (OTC) SABA, and the high percentage of prescriptions for antibiotics warrant country-wide improvements in asthma care and management.
Asthma
;
Bronchodilator Agents
;
Philippines
;
Prescriptions